Welcome to the e-CCO Library!

P316: Inflammatory Bowel Disease and malignancy: What are the predictors of malignancy in Inflammatory Bowel Disease?
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Istemihan, Z.(1)*;Çavuş, B.(1);Bardak, A.E.(2);Kırkoğlu, A.M.(2);Kızıltaş, C.(2);Silay, R.(2);Şenkal, İ.V.(1);İmanov, Z.(1);Nuriyev, K.(1);Rüstemzade, A.(1);Genç, S.(1);Güllüoğlu, M.(3);Çifcibaşı Örmeci, A.(1);Demir, K.(1);Beşışık, F.(1);Kaymakoğlu, S.(1);Akyüz, F.(1);
Created: Friday, 14 July 2023, 11:05 AM
P316: New approaches for IBD management based on text mining of digitalised medical reports and latent class modelling
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bergey F.*1, Saccenti E.2, Jonkers D.3, van den Heuvel T.3, Jeuring S.3, Pierik M.3, Martins dos Santos V.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P316: Ozanimod is an efficacious oral therapy after 5-ASA failure in immunomodulator- and biologic-naive patients with ulcerative colitis: post hoc analysis from True North
Year: 2022
Source: ECCO'22
Authors: Sands, B.E.(1);Dignass, A.(2);Irving, P.(3);Chiorean, M.(4);Long, M.(5);Eren, D.(6);Ahmad, H.A.(6);Osterman, M.T.(6);Petersen, A.(6);Elegbe, A.(6);Ritter, T.(7);Danese, S.(8);
Created: Friday, 11 February 2022, 3:52 PM
P316: Prognosis of patients with inflammatory bowel disease in clinical remission after de-escalation of infliximab maintenance therapy from 8 to 12 weeks
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

J. M. Vázquez-Morón, B. Benítez-Rodríguez*, H. Pallarés-Manrique, M. Ramos-Lora

Created: Friday, 22 February 2019, 9:49 AM
P316: Transanal minimal invasive proctectomy (TaMIP) for perineal Crohn’s disease; a multi-centre prospective cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. Chandrasinghe*1,2,3, F. Di Candido4, J. Warusavitarne2,5, A. Spinelli4,6

Created: Friday, 22 February 2019, 9:41 AM
P317 Key features of bowel ultrasonography in managing inflammatory bowel disease patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Les, R. Iacob, R. Costache, L. Gheorghe, C. Gheorghe

Created: Thursday, 30 January 2020, 10:12 AM
P317: Characterisation of patients with delayed response to ustekinumab for Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. E. Sands*1, A. Oortwijn2, N. Rijnders2, J. Izanec3, C. Gasink3, D. Jacobstein4, O. J. Adedokun4, T. Ma4, L-L. Gao4, J-F. Colombel5, S. Targan6, S. Ghosh7, W. J. Sandborn8

Created: Friday, 22 February 2019, 9:41 AM
P317: Health care costs associated with standard inflammatory bowel disease care in Australia and opportunities to improve care: a tertiary centre study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

B. Jackson*1, R. Ma1, A. Gorelik2, D. Con1, D. Liew2, P. De Cruz1

Created: Friday, 22 February 2019, 9:49 AM
P317: MaRIA score in the assessment of disease activity in patients with ileocolonic Crohn’s disease; the correlation between radiological, endoscopic, and clinical findings
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Crncevic Urek1*, J. Ćurić2, L. Prka3, D. Kardum3, M. Banić3

Created: Thursday, 21 February 2019, 9:14 AM
P317: Patient satisfaction in a joint fistula clinic at a tertiary Inflammatory Bowel Disease centre in the United Kingdom
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Mukhtar, M.S.H.(1)*;Lim, W.J.(2);Tozer, P.(3);Hart , A.(2);
Created: Friday, 14 July 2023, 11:05 AM
P317: Postoperative complications, outcome, quality of life and self-image after ileal pouch-anal anastomosis in patients operated due to acute, severe or chronic, therapy refractory ulcerative colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Balint A.*1, Czinderi V.1, Szucs M.2, Rutka M.1, Farkas K.1, Szepes Z.1, Nagy F.1, Fábián A.1, Bor R.1, Milassin A.1, Lázár G.3, Molnár T.1

Created: Wednesday, 20 February 2019, 10:36 AM
P317: Societal cost-of-illness of Inflammatory Bowel Disease has rapidly increased over the years and differs between continents: A systematic review
Year: 2021
Source: ECCO'21 Virtual
Authors: Van Linschoten, R.(1);Visser, E.(2);Niehot, C.(3);van der Woude, J.(4);Hazelzet, J.(5);van Noord, D.(1);West, R.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P317: Ustekinumab Trough Concentrations Associated with Biochemical Outcomes in Patients with Crohn’s Disease
Year: 2022
Source: ECCO'22
Authors: Straatmijer , T.(1);Biemans , V.B.C.(1);Moes , D.J.A.R.(2);Hoentjen , F.(7);ter Heine , R.(4);Maljaars , P.W.J.(5);Theeuwen , R.(5);Pierik , M.(6);Duijvestein , M.(3);van der Meulen , A.E.(5);
Created: Friday, 11 February 2022, 3:52 PM
P318 Artificial intelligence of the neural network-assistant for differential diagnosis of IBD
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Skalinskaya1, I. Bakulin1, E. Skazyvaeva1, I. Rasmagina1, G. Mashevskii2, N. Shelyakina2, K. Ivanova1, D. Berest1

Created: Thursday, 30 January 2020, 10:12 AM
P318: Accuracy of magnetic resonance enterography for extraluminal complications of Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Pecoraro G.M.*1, Orlando A.2, TesÈ L.3, Solina G.4, Di Mitri R.5, Mocciaro F.5, Renna S.2, Cottone M.2

Created: Wednesday, 20 February 2019, 10:36 AM
P318: Association between faecal calprotectin values and infliximab trough levels in inflammatory bowel disease patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

L. Rodriguez Alonso1*, K. Serra1, E. Santacana2, N. Padullés2, C. Arajol1, P. Gilabert1, J. Orobitg1, F. Rodríguez-Moranta1, H. Colom3, A. Padullés2, J. Bas4, J. Guardiola1

Created: Thursday, 21 February 2019, 9:14 AM
P318: Does anti-tumour necrosis factor therapy decrease the risk of initial intestinal resection after the diagnosis of Crohn’s disease? A retrospective single-centre study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

Y. Nagata*1, M. Esaki1, A. Hirano1, J. Umeno1, Y. Maehata1, T. Torisu1, T. Moriyama1, T. Matsumoto2, T. Kitazono1

Created: Friday, 22 February 2019, 9:49 AM
P318: Intra-dermal with topical imiquimod pre-treatment versus intra-muscular hepatitis B vaccination in inflammatory bowel disease patients: a double-blind randomized controlled trial
Year: 2021
Source: ECCO'21 Virtual
Authors: Ko, K.L.(1);Lam, Y.F.(1);Cheung, K.S.(1);Hung, F.N.(1);Leung, W.K.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P318: Protein FingerPrint assays reflecting neutrophil activity, mucosal damage, and tissue fibrosis are surrogate biomarkers for mucosal healing in pediatric Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Mortensen, J.(1)*;Focht, G.(2);Pehrsson, M.(1);Griffiths, A.M.(3);Alexdóttir, M.S.(1);Quteineh, A.(2);Church, P.C.(3);Baldassano, R.N.(4);Silverstein, J.(5);Karsdal, M.A.(1);Turner, D.(2);
Created: Friday, 14 July 2023, 11:05 AM
P318: Safety of Biological Therapies in Elderly IBD: a Systematic Review and Meta-analysis
Year: 2022
Source: ECCO'22
Authors: Drügg Hahn, G.(1);Golovics, P.(1);Wetwittayakhlang, P.(1);Santa Maria, D.(2);Britto, U.(2);Wild, G.(1);Afif, W.(1);Bessissow, T.(1);Bitton, A.(1);LakatosPhD, P.L.(1);
Created: Friday, 11 February 2022, 3:52 PM